

Lawrence Corey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3438848/publications.pdf>

Version: 2024-02-01

668
papers

82,477
citations

268

141
h-index

642

256
g-index

693
all docs

693
docs citations

693
times ranked

45120
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	27.0	7,910
2	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2187-2201.	27.0	1,954
3	Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. <i>Lancet, The</i> , 2008, 372, 1881-1893.	13.7	1,560
4	Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1990, 322, 941-949.	27.0	1,312
5	Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2002, 34, 909-917.	5.8	1,303
6	Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. <i>Blood</i> , 2002, 100, 4358-4366.	1.4	911
7	Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 1993, 328, 465-470.	27.0	880
8	Genital Herpes Simplex Virus Infections: Clinical Manifestations, Course, and Complications. <i>Annals of Internal Medicine</i> , 1983, 98, 958.	3.9	839
9	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2022, 375, 43-50.	12.6	788
10	Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine. <i>New England Journal of Medicine</i> , 1996, 334, 1011-1018.	27.0	727
11	The Acquisition of Herpes Simplex Virus during Pregnancy. <i>New England Journal of Medicine</i> , 1997, 337, 509-516.	27.0	704
12	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a caseâ€“cohort analysis. <i>Lancet, The</i> , 2008, 372, 1894-1905.	13.7	670
13	Vaccine Prevention of Maternal Cytomegalovirus Infection. <i>New England Journal of Medicine</i> , 2009, 360, 1191-1199.	27.0	667
14	Infections with Herpes Simplex Viruses. <i>New England Journal of Medicine</i> , 1986, 314, 686-691.	27.0	658
15	Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. <i>New England Journal of Medicine</i> , 2004, 350, 11-20.	27.0	658
16	Plasma Viremia in Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1989, 321, 1626-1631.	27.0	635
17	Sexual Practices, Sexually Transmitted Diseases, and the Incidence of Anal Cancer. <i>New England Journal of Medicine</i> , 1987, 317, 973-977.	27.0	624
18	Effect of Serologic Status and Cesarean Delivery on Transmission Rates of Herpes Simplex Virus From Mother to Infant. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 203.	7.4	595

#	ARTICLE	IF	CITATIONS
19	Tâ€cell mediated rejection of geneâ€modified HIVâ€specific cytotoxic T lymphocytes in HIVâ€infected patients. <i>Nature Medicine</i> , 1996, 2, 216-223.	30.7	575
20	Combination Antifungal Therapy for Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2004, 39, 797-802.	5.8	574
21	Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. <i>Blood</i> , 2003, 101, 407-414.	1.4	554
22	Reactivation of Genital Herpes Simplex Virus Type 2 Infection in Asymptomatic Seropositive Persons. <i>New England Journal of Medicine</i> , 2000, 342, 844-850.	27.0	533
23	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	27.0	518
24	Infections with Herpes Simplex Viruses. <i>New England Journal of Medicine</i> , 1986, 314, 749-757.	27.0	517
25	Maternal and Neonatal Herpes Simplex Virus Infections. <i>New England Journal of Medicine</i> , 2009, 361, 1376-1385.	27.0	517
26	Cytotoxic-T-Cell Responses, Viral Load, and Disease Progression in Early Human Immunodeficiency Virus Type 1 Infection. <i>New England Journal of Medicine</i> , 1997, 337, 1267-1274.	27.0	512
27	Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. <i>Lancet, The</i> , 2000, 356, 645-649.	13.7	505
28	Virologic Characteristics of Subclinical and Symptomatic Genital Herpes Infections. <i>New England Journal of Medicine</i> , 1995, 333, 770-775.	27.0	491
29	The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 35, 435-445.	2.1	490
30	Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. <i>Blood</i> , 2000, 96, 2055-2061.	1.4	480
31	A Prospective Study of New Infections with Herpes Simplex Virus Type 1 and Type 2. <i>New England Journal of Medicine</i> , 1999, 341, 1432-1438.	27.0	465
32	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 2348-2360.	27.0	458
33	Neonatal Herpes Simplex Virus Infection in Relation to Asymptomatic Maternal Infection at the Time of Labor. <i>New England Journal of Medicine</i> , 1991, 324, 1247-1252.	27.0	453
34	Mucosal Shedding of Human Herpesvirus 8 in Men. <i>New England Journal of Medicine</i> , 2000, 343, 1369-1377.	27.0	440
35	Adenovirus Infections in Patients Undergoing Bone-Marrow Transplantation. <i>New England Journal of Medicine</i> , 1985, 312, 529-533.	27.0	427
36	A strategic approach to COVID-19 vaccine R&D. <i>Science</i> , 2020, 368, 948-950.	12.6	419

#	ARTICLE	IF	CITATIONS
37	Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection. JAMA - Journal of the American Medical Association, 1999, 282, 331-40.	7.4	418
38	A Population-Based Study of Primary Human Herpesvirus 6 Infection. New England Journal of Medicine, 2005, 352, 768-776.	27.0	417
39	Modeling Plasma Virus Concentration during Primary HIV Infection. Journal of Theoretical Biology, 2000, 203, 285-301.	1.7	416
40	Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood, 2004, 103, 1527-1533.	1.4	414
41	Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 371, 2109-2119.	13.7	412
42	Recurrences after Oral and Genital Herpes Simplex Virus Infection. New England Journal of Medicine, 1987, 316, 1444-1449.	27.0	408
43	Predictors of Morbidity and Mortality in Neonates with Herpes Simplex Virus Infections. New England Journal of Medicine, 1991, 324, 450-454.	27.0	407
44	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. New England Journal of Medicine, 2021, 385, 1774-1785.	27.0	402
45	Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients. JAMA - Journal of the American Medical Association, 2008, 300, 413.	7.4	401
46	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Medicine, 1999, 5, 651-655.	30.7	400
47	High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV) Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effects of Primary CMV Infection. Journal of Infectious Diseases, 2002, 185, 273-282.	4.0	381
48	A Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus Infection. New England Journal of Medicine, 1991, 324, 444-449.	27.0	375
49	A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus Infection. New England Journal of Medicine, 1984, 310, 1551-1556.	27.0	366
50	Genital ulceration as a risk factor for human immunodeficiency virus infection. Aids, 1988, 2, 47-50.	2.2	365
51	Risk of Recurrence after First Episodes of Genital Herpes. New England Journal of Medicine, 1981, 305, 315-319.	27.0	361
52	Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood, 2005, 106, 2641-2645.	1.4	355
53	Influenza Infections after Hematopoietic Stem Cell Transplantation: Risk Factors, Mortality, and the Effect of Antiviral Therapy. Clinical Infectious Diseases, 2004, 39, 1300-1306.	5.8	345
54	Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nature Medicine, 2009, 15, 886-892.	30.7	341

#	ARTICLE	IF	CITATIONS
55	SARS-CoV-2 Variants in Patients with Immunosuppression. <i>New England Journal of Medicine</i> , 2021, 385, 562-566.	27.0	333
56	Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. <i>Lancet Infectious Diseases</i> , 2011, 11, 507-515.	9.1	330
57	A Trial of Topical Acyclovir in Genital Herpes Simplex Virus Infections. <i>New England Journal of Medicine</i> , 1982, 306, 1313-1319.	27.0	328
58	In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. <i>Nature Medicine</i> , 1999, 5, 34-41.	30.7	324
59	Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. <i>Journal of Experimental Medicine</i> , 2007, 204, 595-603.	8.5	315
60	Clinical Outcomes of Human Herpesvirus 6 Reactivation after Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2005, 40, 932-940.	5.8	313
61	Human Herpesvirus 6 in Lung Tissue from Patients with Pneumonitis after Bone Marrow Transplantation. <i>New England Journal of Medicine</i> , 1993, 329, 156-161.	27.0	312
62	Valganciclovir Reduces T Cell Activation in HIV-Infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1474-1483.	4.0	308
63	The Polymicrobial Origin of Intestinal Infections in Homosexual Men. <i>New England Journal of Medicine</i> , 1983, 309, 576-582.	27.0	296
64	Association between Culturable Human Immunodeficiency Virus Type 1 (HIV-1) in Semen and HIV-1 RNA Levels in Semen and Blood: Evidence for Compartmentalization of HIV-1 between Semen and Blood. <i>Journal of Infectious Diseases</i> , 1998, 177, 320-330.	4.0	296
65	Polymerase Chain Reaction for Detection of Herpes Simplex Virus (HSV) DNA on Mucosal Surfaces: Comparison with HSV Isolation in Cell Culture. <i>Journal of Infectious Diseases</i> , 2003, 188, 1345-1351.	4.0	293
66	Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. <i>Blood</i> , 2001, 98, 573-578.	1.4	284
67	Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14 ⁺ Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2002, 76, 707-716.	3.4	282
68	Effects on Infants of a First Episode of Genital Herpes during Pregnancy. <i>New England Journal of Medicine</i> , 1987, 317, 1246-1251.	27.0	278
69	Underdiagnosis of Genital Herpes by Current Clinical and Viral-Isolation Procedures. <i>New England Journal of Medicine</i> , 1992, 326, 1533-1539.	27.0	275
70	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. <i>New England Journal of Medicine</i> , 2022, 386, 531-543.	27.0	274
71	Comparison of Real-Time PCR Assays with Fluorescent-Antibody Assays for Diagnosis of Respiratory Virus Infections in Children. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2382-2388.	3.9	273
72	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021, 384, 1003-1014.	27.0	270

#	ARTICLE	IF	CITATIONS
73	Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission. <i>Science Translational Medicine</i> , 2011, 3, 77ra29.	12.4	265
74	Herpes Simplex Virus Proctitis in Homosexual Men. <i>New England Journal of Medicine</i> , 1983, 308, 868-871.	27.0	260
75	After the pandemic: perspectives on the future trajectory of COVID-19. <i>Nature</i> , 2021, 596, 495-504.	27.8	260
76	Immune surveillance by CD8 ⁺ skin-resident T _H 1 cells in human herpes virus infection. <i>Nature</i> , 2013, 497, 494-497.	27.8	257
77	Optimization of Quantitative Detection of Cytomegalovirus DNA in Plasma by Real-Time PCR. <i>Journal of Clinical Microbiology</i> , 2004, 42, 1142-1148.	3.9	241
78	Frequency of Acquisition of First-episode Genital Infection with Herpes Simplex Virus from Symptomatic and Asymptomatic Source Contacts. <i>Sexually Transmitted Diseases</i> , 1985, 12, 33-39.	1.7	240
79	Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research. <i>Clinical Microbiology Reviews</i> , 2003, 16, 96-113.	13.6	239
80	Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons With HSV-2 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1441.	7.4	237
81	Isolation of Human Immunodeficiency Virus from Genital Ulcers in Nairobi Prostitutes. <i>Journal of Infectious Diseases</i> , 1989, 160, 380-384.	4.0	236
82	Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , 1999, 94, 4029-4035.	1.4	236
83	Rapidly Cleared Episodes of Herpes Simplex Virus Reactivation in Immunocompetent Adults. <i>Journal of Infectious Diseases</i> , 2008, 198, 1141-1149.	4.0	233
84	Sexual Transmission of Hepatitis A in Homosexual Men. <i>New England Journal of Medicine</i> , 1980, 302, 435-438.	27.0	228
85	Development of a High-Throughput Quantitative Assay for Detecting Herpes Simplex Virus DNA in Clinical Samples. <i>Journal of Clinical Microbiology</i> , 1999, 37, 1941-1947.	3.9	226
86	Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. <i>Blood</i> , 2003, 102, 3060-3067.	1.4	225
87	Brief Communication: Fatal Human Metapneumovirus Infection in Stem-Cell Transplant Recipients. <i>Annals of Internal Medicine</i> , 2006, 144, 344.	3.9	225
88	Frequent Detection of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) DNA in Saliva of Human Immunodeficiency Virus-Infected Men: Clinical and Immunologic Correlates. <i>Journal of Infectious Diseases</i> , 1997, 176, 94-102.	4.0	224
89	Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. <i>BMJ: British Medical Journal</i> , 1994, 309, 1325-1329.	2.3	221
90	Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. <i>Blood</i> , 2002, 99, 1978-1985.	1.4	220

#	ARTICLE	IF	CITATIONS
91	Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. <i>Nature Medicine</i> , 2011, 17, 366-371.	30.7	220
92	Application of the Polymerase Chain Reaction to the Diagnosis and Management of Neonatal Herpes Simplex Virus Disease. <i>Journal of Infectious Diseases</i> , 1996, 174, 1162-1167.	4.0	219
93	Genital Herpes Has Played a More Important Role than Any Other Sexually Transmitted Infection in Driving HIV Prevalence in Africa. <i>PLoS ONE</i> , 2008, 3, e2230.	2.5	219
94	Frequency of Symptomatic and Asymptomatic Herpes Simplex Virus Type 2 Reactivations among Human Immunodeficiency Virus-Infected Men. <i>Journal of Infectious Diseases</i> , 1998, 178, 1616-1622.	4.0	218
95	Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. <i>Blood</i> , 2003, 101, 4195-4200.	1.4	214
96	Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. <i>Blood</i> , 2007, 110, 1681-1688.	1.4	208
97	A Pilot Study of Low-Dose Zidovudine in Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1990, 323, 1015-1021.	27.0	206
98	Genital Herpes and Public Health. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 791.	7.4	206
99	Effect of Antivirals on Human Herpesvirus 6 Replication in Hematopoietic Stem Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2002, 34, 309-317.	5.8	206
100	Prospects for a safe COVID-19 vaccine. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	204
101	Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). <i>Journal of Infectious Diseases</i> , 2012, 206, 258-266.	4.0	202
102	Herpes Simplex Virus Inhibits Apoptosis through the Action of Two Genes, Us5 and Us3. <i>Journal of Virology</i> , 1999, 73, 8950-8957.	3.4	198
103	DIFFERENCE BETWEEN HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2 NEONATAL ENCEPHALITIS IN NEUROLOGICAL OUTCOME. <i>Lancet, The</i> , 1988, 331, 1-4.	13.7	195
104	A Framework for Assessing Immunological Correlates of Protection in Vaccine Trials. <i>Journal of Infectious Diseases</i> , 2007, 196, 1304-1312.	4.0	195
105	Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV-1 gp120, HIV-1 SF2 Recombinant gp120, or Both Vaccines in Seronegative Adults. <i>Journal of Infectious Diseases</i> , 1998, 177, 1230-1246.	4.0	194
106	Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. <i>Blood</i> , 2004, 103, 1632-1634.	1.4	191
107	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	12.6	191
108	Quantitation of BK Virus Load in Serum for the Diagnosis of BK Virus-Associated Nephropathy in Renal Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2001, 183, 1669-1672.	4.0	189

#	ARTICLE	IF	CITATIONS
109	Dual HIV-1 infection associated with rapid disease progression. <i>Lancet</i> , The, 2004, 363, 619-622.	13.7	189
110	Intravenous Acyclovir for the Treatment of Primary Genital Herpes. <i>Annals of Internal Medicine</i> , 1983, 98, 914.	3.9	187
111	Changes in Plasma Human Immunodeficiency Virus Type 1 RNA Associated with Herpes Simplex Virus Reactivation and Suppression. <i>Journal of Infectious Diseases</i> , 2002, 186, 1718-1725.	4.0	187
112	Herpes Simplex: Insights on Pathogenesis and Possible Vaccines. <i>Annual Review of Medicine</i> , 2008, 59, 381-395.	12.2	187
113	MEDICINE: Enhanced: The Need for a Global HIV Vaccine Enterprise. <i>Science</i> , 2003, 300, 2036-2039.	12.6	186
114	One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. <i>Blood</i> , 2007, 110, 3071-3077.	1.4	186
115	Sexually Transmitted Diseases in Victims of Rape. <i>New England Journal of Medicine</i> , 1990, 322, 713-716.	27.0	185
116	Cyclophosphamide metabolism is affected by azole antifungals. <i>Blood</i> , 2004, 103, 1557-1559.	1.4	181
117	Decay of the HIV Reservoir in Patients Receiving Antiretroviral Therapy for Extended Periods: Implications for Eradication of Virus. <i>Journal of Infectious Diseases</i> , 2007, 195, 1762-1764.	4.0	180
118	Phase 1 Evaluation of the Respiratory Syncytial Virus-Specific Monoclonal Antibody Palivizumab in Recipients of Hematopoietic Stem Cell Transplants. <i>Journal of Infectious Diseases</i> , 2001, 184, 350-354.	4.0	179
119	Immune correlates of vaccine protection against HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 310v7.	12.4	179
120	Herpes Simplex Virus (HSV) Suppression with Valacyclovir Reduces Rectal and Blood Plasma HIV-1 Levels in HIV-1/HSV-2-Seropositive Men: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial. <i>Journal of Infectious Diseases</i> , 2007, 196, 1500-1508.	4.0	176
121	Activation of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Lytic Replication by Human Cytomegalovirus. <i>Journal of Virology</i> , 2001, 75, 1378-1386.	3.4	170
122	Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features. <i>Hepatology</i> , 1995, 22, 1-9.	7.3	169
123	A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 836-843.	1.3	169
124	Airflow Decline after Myeloablative Allogeneic Hematopoietic Cell Transplantation: The Role of Community Respiratory Viruses. <i>Journal of Infectious Diseases</i> , 2006, 193, 1619-1625.	4.0	168
125	Genital Herpes Complicating Pregnancy. <i>Obstetrics and Gynecology</i> , 2005, 106, 845-856.	2.4	167
126	A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2002, 99, 2712-2719.	1.4	166

#	ARTICLE	IF	CITATIONS
127	BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. <i>Blood</i> , 2005, 106, 1130-1132.	1.4	161
128	Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. <i>Blood</i> , 2010, 115, 2088-2094.	1.4	161
129	High-Throughput Quantitative Analysis of Hepatitis B Virus DNA in Serum Using the TaqMan Fluorogenic Detection System. <i>Hepatology</i> , 2000, 32, 626-629.	7.3	155
130	A nationwide outbreak of Reye's syndrome. <i>American Journal of Medicine</i> , 1976, 61, 615-625.	1.5	154
131	The Frequency of Unrecognized Type 2 Herpes Simplex Virus Infection Among Women Implications for the Control of Genital Herpes. <i>Sexually Transmitted Diseases</i> , 1990, 17, 90-94.	1.7	151
132	Innate Immunity in Human Immunodeficiency Virus Infection: Effect of Viremia on Natural Killer Cell Function. <i>Journal of Infectious Diseases</i> , 2003, 187, 1038-1045.	4.0	151
133	Successful Modification of a pp65 Antigenemia-Based Early Treatment Strategy for Prevention of Cytomegalovirus Disease in Allogeneic Marrow Transplant Recipients. <i>Blood</i> , 1999, 93, 1781-1782.	1.4	150
134	Valacyclovir and Acyclovir for Suppression of Shedding of Herpes Simplex Virus in the Genital Tract. <i>Journal of Infectious Diseases</i> , 2004, 190, 1374-1381.	4.0	150
135	Clinical Reactivation of Genital Herpes Simplex Virus Infection Decreases in Frequency over Time. <i>Annals of Internal Medicine</i> , 1999, 131, 14.	3.9	149
136	Human Herpesvirus 6 Infections after Bone Marrow Transplantation: Clinical and Virologic Manifestations. <i>Journal of Infectious Diseases</i> , 1999, 179, 311-318.	4.0	149
137	Effect of Combination Antiretroviral Therapy on Tâ€Cell Immunity in Acute Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2000, 181, 121-131.	4.0	148
138	Comprehensive Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Gamma Interferon-Secreting CD8 + T Cells in Primary HIV-1 Infection. <i>Journal of Virology</i> , 2003, 77, 6867-6878.	3.4	148
139	Human Papillomaviruses, Herpes Simplex Viruses, and the Risk of Oral Cancer in Men. <i>American Journal of Epidemiology</i> , 1992, 135, 1093-1102.	3.4	147
140	Valganciclovir for Suppression of Human Herpesvirusâ€8 Replication: A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Crossover Trial. <i>Journal of Infectious Diseases</i> , 2008, 198, 23-30.	4.0	147
141	A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial of Cidofovir Gel for the Treatment of Acyclovirâ€Unresponsive Mucocutaneous Herpes Simplex Virus Infection in Patients with AIDS. <i>Journal of Infectious Diseases</i> , 1997, 176, 892-898.	4.0	146
142	Immunization with Recombinant Canarypox Vectors Expressing Membrane-Anchored Glycoprotein 120 Followed by Glycoprotein 160 Boosting Fails to Generate Antibodies That Neutralize R5 Primary Isolates of Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 2019-2035.	1.1	146
143	Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1687-1699.	2.0	145
144	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	12.6	145

#	ARTICLE	IF	CITATIONS
145	Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 341-352.	2.0	144
146	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120â€MF59 in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100.	27.0	144
147	Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 Lesions. <i>Journal of Infectious Diseases</i> , 1994, 169, 956-961.	4.0	142
148	Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2010, 375, 824-833.	13.7	142
149	Safety and Immunogenicity of a Canarypoxâ€Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higherâ€and Lowerâ€Risk Volunteers. <i>Journal of Infectious Diseases</i> , 2001, 183, 1343-1352.	4.0	140
150	Longâ€Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis Infection. <i>Journal of Infectious Diseases</i> , 2001, 184, 1236-1245.	4.0	140
151	Natural History of Genital Herpes Simplex Virus Type 1 Infection. <i>Sexually Transmitted Diseases</i> , 2003, 30, 174-177.	1.7	139
152	Pharmacokinetics of acyclovir in the term human pregnancy and neonate. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 164, 569-576.	1.3	138
153	The Relationship between Condom Use and Herpes Simplex Virus Acquisition. <i>Annals of Internal Medicine</i> , 2005, 143, 707.	3.9	138
154	<i>Chlamydia pneumoniae</i> , Herpes Simplex Virus Type 1, and Cytomegalovirus and Incident Myocardial Infarction and Coronary Heart Disease Death in Older Adults. <i>Circulation</i> , 2000, 102, 2335-2340.	1.6	134
155	Quantitative Stability of DNA after Extended Storage of Clinical Specimens as Determined by Real-Time PCR. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2609-2611.	3.9	134
156	Rapid Accumulation of Human Immunodeficiency Virus (HIV) in Lymphatic Tissue Reservoirs during Acute and Early HIV Infection: Implications for Timing of Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2000, 181, 354-357.	4.0	132
157	Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 494-503.	2.0	132
158	Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. <i>Clinical Microbiology Reviews</i> , 2016, 29, 149-161.	13.6	132
159	Functional Analysis of the Human Cytomegalovirus US28 Gene by Insertion Mutagenesis with the Green Fluorescent Protein Gene. <i>Journal of Virology</i> , 1998, 72, 8158-8165.	3.4	132
160	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. <i>New England Journal of Medicine</i> , 2022, 386, 847-860.	27.0	132
161	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). <i>PLoS ONE</i> , 2011, 6, e21225.	2.5	131
162	Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection. <i>Journal of Virology</i> , 1998, 72, 4288-4296.	3.4	131

#	ARTICLE	IF	CITATIONS
163	Transmission of Genital Herpes in Couples with One Symptomatic and One Asymptomatic Partner: A Prospective Study. <i>Journal of Infectious Diseases</i> , 1988, 157, 1169-1177.	4.0	129
164	Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy. <i>Nature Medicine</i> , 1998, 4, 341-345.	30.7	129
165	Rhinovirus Infections in Hematopoietic Stem Cell Transplant Recipients with Pneumonia. <i>Clinical Infectious Diseases</i> , 2003, 36, 1139-1143.	5.8	129
166	Herpes Simplex Virus (HSV) Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2/HIV-1 Coinfected Women: A Randomized, Placebo-Controlled, Cross-Over Trial. <i>Journal of Infectious Diseases</i> , 2008, 198, 1804-1808.	4.0	129
167	Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk. <i>PLoS ONE</i> , 2010, 5, e12598.	2.5	129
168	Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. <i>Blood</i> , 2011, 117, 5050-5056.	1.4	129
169	Association between cervical shedding of herpes simplex virus and HIV-1. <i>Aids</i> , 2002, 16, 2425-2430.	2.2	128
170	Helicase-Primase Inhibitor Pritelivir for HSV-2 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 201-210.	27.0	128
171	HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. <i>Blood</i> , 2011, 117, 5243-5249.	1.4	123
172	Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1220-1226.	2.0	122
173	HHV-6 Reactivation and Associated Sequelae after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1700-1708.	2.0	121
174	Selection on the Human Immunodeficiency Virus Type 1 Proteome following Primary Infection. <i>Journal of Virology</i> , 2006, 80, 9519-9529.	3.4	118
175	CD8 CTL from Genital Herpes Simplex Lesions: Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutaneous Cells. <i>Journal of Immunology</i> , 2001, 166, 4049-4058.	0.8	117
176	The etiology of anorectal infections in homosexual men. <i>American Journal of Medicine</i> , 1981, 71, 395-406.	1.5	116
177	BK Virus Infection in Hematopoietic Stem Cell Transplant Recipients: Frequency, Risk Factors, and Association with Postengraftment Hemorrhagic Cystitis. <i>Clinical Infectious Diseases</i> , 2004, 39, 1861-1865.	5.8	116
178	Recurrent genital herpes simplex virus infection in pregnancy: Infant outcome and frequency of asymptomatic recurrences. <i>American Journal of Obstetrics and Gynecology</i> , 1982, 143, 75-84.	1.3	115
179	Virological, Clinical, and Ophthalmologic Features of Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2001, 32, 214-219.	5.8	115
180	Analysis of Genetic Polymorphisms in CCR5, CCR2, Stromal Cell-Derived Factor-1, RANTES, and Dendritic Cell-Specific Intercellular Adhesion Molecule-3 Grabbing Nonintegrin in Seronegative Individuals Repeatedly Exposed to HIV-1. <i>Journal of Infectious Diseases</i> , 2004, 190, 1055-1058.	4.0	115

#	ARTICLE	IF	CITATIONS
181	Cytomegalovirus infection in homosexual men. <i>American Journal of Medicine</i> , 1987, 82, 593-601.	1.5	114
182	Human Herpesvirus 6 Reactivation and Encephalitis in Allogeneic Bone Marrow Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2001, 33, 763-771.	5.8	114
183	Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices. <i>Clinical Infectious Diseases</i> , 2015, 61, 31-39.	5.8	114
184	CD27 Expression Promotes Long-Term Survival of Functional Effectorâ€“Memory CD8+Cytotoxic T Lymphocytes in HIV-infected Patients. <i>Journal of Experimental Medicine</i> , 2004, 200, 1407-1417.	8.5	113
185	Early and Persistent Human Immunodeficiency Virus Type 1 (HIVâ€“1)â€“Specific T Helper Dysfunction in Blood and Lymph Nodes following Acute HIVâ€“1 Infection. <i>Journal of Infectious Diseases</i> , 1999, 180, 278-284.	4.0	112
186	Productive Infection of T Cells in Lymphoid Tissues during Primary and Early Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2001, 183, 555-562.	4.0	112
187	Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18973-18978.	7.1	112
188	Clinical Outcomes Associated With Respiratory Virus Detection Before Allogeneic Hematopoietic Stem Cell Transplant. <i>Clinical Infectious Diseases</i> , 2015, 61, 192-202.	5.8	112
189	Cervical Shedding of Herpes Simplex Virus in Human Immunodeficiency Virusâ€“Infected Women: Effects of Hormonal Contraception, Pregnancy, and Vitamin A Deficiency. <i>Journal of Infectious Diseases</i> , 2000, 181, 58-63.	4.0	110
190	Cellular Immune Response in Genital Herpes Simplex Virus Infection. <i>New England Journal of Medicine</i> , 1978, 299, 986-991.	27.0	109
191	HSV and Glycoprotein J Inhibit Caspase Activation and Apoptosis Induced by Granzyme B or Fas. <i>Journal of Immunology</i> , 2001, 167, 3928-3935.	0.8	109
192	Detection of Epstein-Barr Virus DNA in Sera from Transplant Recipients with Lymphoproliferative Disorders. <i>Journal of Clinical Microbiology</i> , 1999, 37, 1113-1116.	3.9	109
193	Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. <i>Journal of Clinical Investigation</i> , 2001, 107, 505-517.	8.2	109
194	Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. <i>Journal of Medical Virology</i> , 2005, 76, 350-355.	5.0	108
195	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 388-396.	9.1	108
196	Synergistic Copathogens â€“ HIV-1 and HSV-2. <i>New England Journal of Medicine</i> , 2007, 356, 854-856.	27.0	107
197	Twoâ€“Day Regimen of Acyclovir for Treatment of Recurrent Genital Herpes Simplex Virus Type 2 Infection. <i>Clinical Infectious Diseases</i> , 2002, 34, 944-948.	5.8	106
198	Use of Longâ€“Term Suppressive Acyclovir after Hematopoietic Stemâ€“Cell Transplantation: Impact on Herpes Simplex Virus (HSV) Disease and Drugâ€“Resistant HSV Disease. <i>Journal of Infectious Diseases</i> , 2007, 196, 266-270.	4.0	106

#	ARTICLE	IF	CITATIONS
199	Frequent Reactivation of Herpes Simplex Virus among HIV-1 Infected Patients Treated with Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2004, 190, 693-696.	4.0	105
200	Detection and quantification of human metapneumovirus in pediatric specimens by real-time RT-PCR. <i>Journal of Clinical Virology</i> , 2005, 33, 299-305.	3.1	105
201	Treatment of Primary Human Immunodeficiency Virus Type 1 Infection with Potent Antiretroviral Therapy Reduces Frequency of Rapid Progression to AIDS. <i>Journal of Infectious Diseases</i> , 2001, 183, 1466-1475.	4.0	104
202	Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. <i>Lancet</i> , The, 2012, 379, 641-647.	13.7	104
203	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002435.	8.4	104
204	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. <i>Journal of Clinical Investigation</i> , 2002, 110, 537-548.	8.2	103
205	HIV Vaccines: New Frontiers in Vaccine Development. <i>Clinical Infectious Diseases</i> , 2006, 43, 500-511.	5.8	102
206	Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 44, 203-212.	2.1	101
207	Herpes Simplex Virus Type 1 Renders Infected Cells Resistant to Cytotoxic T-Lymphocyte-Induced Apoptosis. <i>Journal of Virology</i> , 1998, 72, 436-441.	3.4	101
208	Virus Population Homogenization following Acute Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2002, 76, 11953-11959.	3.4	100
209	Frequent Release of Low Amounts of Herpes Simplex Virus from Neurons: Results of a Mathematical Model. <i>Science Translational Medicine</i> , 2009, 1, 7ra16.	12.4	100
210	Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: Characteristics of respiratory and catheter-related infections. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 361-369.	2.0	99
211	Topical Resiquimod 0.01% Gel Decreases Herpes Simplex Virus Type 2 Genital Shedding: A Randomized, Controlled Trial. <i>Journal of Infectious Diseases</i> , 2007, 195, 1324-1331.	4.0	98
212	Etiology of cervical inflammation. <i>American Journal of Obstetrics and Gynecology</i> , 1986, 154, 556-564.	1.3	97
213	Frequent and Asymptomatic Oropharyngeal Shedding of Human Herpesvirus 8 among Immunocompetent Men. <i>Journal of Infectious Diseases</i> , 2007, 195, 30-36.	4.0	97
214	Subclinical Viremia Increases Risk for Chronic Allograft Injury in Pediatric Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1579-1586.	6.1	97
215	Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections. <i>American Journal of Medicine</i> , 1982, 73, 326-334.	1.5	96
216	Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8 ⁺ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. Fred Hutchinson Cancer Research Center and the University of Washington. <i>Human Gene Therapy</i> , 1992, 3, 319-338.	2.7	95

#	ARTICLE	IF	CITATIONS
217	Cytomegalovirus (CMV) DNA Load in Plasma for the Diagnosis of CMV Disease before Engraftment in Hematopoietic Stemâ€Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2001, 183, 377-382.	4.0	95
218	Diversity of the CD8 + T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital Herpes. <i>Journal of Virology</i> , 2006, 80, 5509-5515.	3.4	95
219	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	8.2	95
220	Herpesvirus Infections in Persons Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1995, 21, S114-S120.	5.8	94
221	Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. <i>Vaccine</i> , 2006, 24, 6893-6904.	3.8	93
222	Viremia in neonatal herpes simplex virus infections. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 487-489.	2.0	92
223	Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection. <i>Journal of Infectious Diseases</i> , 1993, 168, 1387-1395.	4.0	91
224	Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. <i>American Journal of Medicine</i> , 1990, 88, 465-469.	1.5	90
225	Tipping the scales of herpes simplex virus reactivation: The important responses are local. <i>Nature Medicine</i> , 1998, 4, 381-382.	30.7	89
226	Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. <i>Journal of Infectious Diseases</i> , 1998, 177, 310-319.	4.0	88
227	Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1â€Uninfected Adults: AIDS Vaccine Evaluation Group Protocol O22A. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 254-261.	2.1	88
228	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , 2019, 26, 336-346.e3.	11.0	88
229	Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. <i>Journal of Medical Virology</i> , 1985, 17, 153-166.	5.0	87
230	Hepatitis C Virus Replication in Transfected and Serum-Infected Cultured Human Fetal Hepatocytes. <i>American Journal of Pathology</i> , 2007, 170, 478-489.	3.8	87
231	The Use of Nonhuman Primate Models in HIV Vaccine Development. <i>PLoS Medicine</i> , 2008, 5, e173.	8.4	87
232	Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. <i>Nature Medicine</i> , 2013, 19, 280-288.	30.7	87
233	Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. <i>Haematologica</i> , 2009, 94, 1101-1108.	3.5	86
234	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , 2018, 5, e366-e378.	4.7	86

#	ARTICLE	IF	CITATIONS
235	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228.	3.9	86
236	Assessment of Hepatitis C Virus Quasispecies Heterogeneity by Gel Shift Analysis: Correlation with Response to Interferon Therapy. <i>Journal of Infectious Diseases</i> , 1997, 175, 1101-1107.	4.0	85
237	Safety and Tolerability of Oseltamivir Prophylaxis in Hematopoietic Stem Cell Transplant Recipients: A Retrospective Case-Control Study. <i>Clinical Infectious Diseases</i> , 2007, 45, 187-193.	5.8	85
238	Genital herpes in pregnancy: Risk factors associated with recurrences and asymptomatic viral shedding. <i>American Journal of Obstetrics and Gynecology</i> , 1985, 153, 24-30.	1.3	84
239	HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. <i>Journal of Clinical Investigation</i> , 2000, 105, 1407-1417.	8.2	84
240	Persistence of Extraordinarily Low Levels of Genetically Homogeneous Human Immunodeficiency Virus Type 1 in Exposed Seronegative Individuals. <i>Journal of Virology</i> , 2003, 77, 6108-6116.	3.4	83
241	Compartmentalization of Human Immunodeficiency Virus Type 1 between Blood Monocytes and CD4 + T Cells during Infection. <i>Journal of Virology</i> , 2004, 78, 7883-7893.	3.4	83
242	Respiratory Virus Pneumonia after Hematopoietic Cell Transplantation (HCT): Associations between Viral Load in Bronchoalveolar Lavage Samples, Viral RNA Detection in Serum Samples, and Clinical Outcomes of HCT. <i>Journal of Infectious Diseases</i> , 2010, 201, 1404-1413.	4.0	82
243	Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 281-289.	2.0	81
244	Quantitative Real-time Polymerase Chain Reaction for Detection of Adenovirus after T Cell Replete Hematopoietic Cell Transplantation: Viral Load as a Marker for Invasive Disease. <i>Clinical Infectious Diseases</i> , 2007, 45, 958-965.	5.8	81
245	Genital Herpes in a Primary Care Clinic. <i>Sexually Transmitted Diseases</i> , 1997, 24, 149-155.	1.7	80
246	Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial. <i>PLoS ONE</i> , 2011, 6, e16986.	2.5	80
247	Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 683-693.	1.1	79
248	Evidence of Latency and Reactivation of Both Herpes Simplex Virus (HSV) 1 and HSV 2 in the Genital Region. <i>Journal of Infectious Diseases</i> , 1998, 177, 1069-1072.	4.0	78
249	Genital Shedding of Herpes Simplex Virus among Men. <i>Journal of Infectious Diseases</i> , 2002, 186, S34-S39.	4.0	78
250	The need and challenges for development of an Epstein-Barr virus vaccine. <i>Vaccine</i> , 2013, 31, B194-B196.	3.8	77
251	Reactivities of Human Sera with Human Herpesvirus-8-Infected BCBL-1 Cells and Identification of HHV-8-Specific Proteins and Glycoproteins and the Encoding cDNAs. <i>Virology</i> , 1998, 243, 208-217.	2.4	76
252	Correlates of Prevalent and Incident Kaposi's Sarcoma Associated Herpesvirus Infection in Men Who Have Sex with Men. <i>Journal of Infectious Diseases</i> , 2002, 185, 990-993.	4.0	76

#	ARTICLE	IF	CITATIONS
253	Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults. Sexually Transmitted Diseases, 2016, 43, 756-760.	1.7	76
254	Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: Relationship to preterm labor. Obstetrics and Gynecology, 1996, 87, 483-488.	2.4	75
255	HERPES SIMPLEX VIRUSâ€™2 INFECTION. Infectious Disease Clinics of North America, 1998, 12, 47-61.	5.1	75
256	Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen. Journal of Infectious Diseases, 1998, 177, 301-309.	4.0	75
257	The HIV Protease Inhibitor Nelfinavir Inhibits Kaposi's Sarcoma-Associated Herpesvirus Replication In Vitro. Antimicrobial Agents and Chemotherapy, 2011, 55, 2696-2703.	3.2	74
258	High Asymptomatic Carriage With the Omicron Variant in South Africa. Clinical Infectious Diseases, 2022, 75, e289-e292.	5.8	74
259	A Collaborative Study of Patient-Initiated Treatment of Recurrent Genital Herpes with Topical Acyclovir or Placebo. Journal of Infectious Diseases, 1984, 150, 1-6.	4.0	73
260	Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. Virology, 2008, 374, 229-233.	2.4	73
261	A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine, 2006, 24, 914-920.	3.8	72
262	Approaches to preventative and therapeutic HIV vaccines. Current Opinion in Virology, 2016, 17, 104-109.	5.4	72
263	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. Journal of Clinical Investigation, 2002, 110, 537-548.	8.2	72
264	Characteristics of HIV-1 Discordant Couples Enrolled in a Trial of HSV-2 Suppression to Reduce HIV-1 Transmission: The Partners Study. PLoS ONE, 2009, 4, e5272.	2.5	71
265	Clinical Correlates of Herpes Simplex Virus Viremia among Hospitalized Adults. Clinical Infectious Diseases, 2009, 49, 1295-1301.	5.8	71
266	Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. Journal of Clinical Microbiology, 2021, 59, e0052721.	3.9	71
267	Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biology of Blood and Marrow Transplantation, 2004, 10, 58-64.	2.0	70
268	Comparative Efficacy of Famciclovir and Valacyclovir for Suppression of Recurrent Genital Herpes and Viral Shedding. Sexually Transmitted Diseases, 2006, 33, 529-533.	1.7	70
269	Herpes Simplex Virus Viremia during Primary Genital Infection. Journal of Infectious Diseases, 2008, 198, 31-34.	4.0	70
270	Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 694-703.	2.0	70

#	ARTICLE	IF	CITATIONS
271	Pretransplantation Respiratory Syncytial Virus Infection: Impact of a Strategy to Delay Transplantation. <i>Clinical Infectious Diseases</i> , 2004, 39, 673-680.	5.8	69
272	Selection for Human Immunodeficiency Virus Type 1 Recombinants in a Patient with Rapid Progression to AIDS. <i>Journal of Virology</i> , 2002, 76, 10674-10684.	3.4	68
273	Sensitive Method for Detection of Human Herpesviruses 6 and 7 in Saliva Collected in Field Studies. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1981-1983.	3.9	68
274	Intermittent Shedding of Human Immunodeficiency Virus in Semen: Implications for Sexual Transmission. <i>Journal of Urology</i> , 1995, 154, 1035-1040.	0.4	67
275	Toxicity and Efficacy of Daily Dapsone as <i>Pneumocystis jiroveci</i> Prophylaxis after Hematopoietic Stem Cell Transplantation: A Case-Control Study. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 521-529.	2.0	67
276	Persistent Genital Herpes Simplex Virus-2 Shedding Years Following the First Clinical Episode. <i>Journal of Infectious Diseases</i> , 2011, 203, 180-187.	4.0	67
277	Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2495.	7.4	67
278	Markers of Viral Infection in Monozygotic Twins Discordant for Chronic Fatigue Syndrome. <i>Clinical Infectious Diseases</i> , 2002, 35, 518-525.	5.8	66
279	Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. <i>BMC Infectious Diseases</i> , 2005, 5, 84.	2.9	66
280	High-Dose Recombinant Canarypox Vaccine Expressing HIV-1 Protein, in Seronegative Human Subjects. <i>Journal of Infectious Diseases</i> , 2005, 192, 1249-1259.	4.0	66
281	Phase I Study of a Herpes Simplex Virus Type 2 (HSV-2) DNA Vaccine Administered to Healthy, HSV-2-Seronegative Adults by a Needle-Free Injection System. <i>Vaccine Journal</i> , 2008, 15, 1638-1643.	3.1	65
282	Presentation of neonatal herpes simplex virus infections. <i>Pediatric Infectious Disease Journal</i> , 1986, 5, 309-314.	2.0	64
283	A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 907-919.	1.1	64
284	Herpes Simplex Virus Type 2 Shedding in Human Immunodeficiency Virus-Negative Men Who Have Sex with Men: Frequency, Patterns, and Risk Factors. <i>Clinical Infectious Diseases</i> , 2000, 30, 261-267.	5.8	64
285	Human Herpesvirus 8 in the Prostate Glands of Men with Kaposi's Sarcoma. <i>Journal of Virology</i> , 1998, 72, 6223-6227.	3.4	64
286	Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. <i>Pediatric Blood and Cancer</i> , 2010, 54, 670-674.	1.5	63
287	Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem Cell Transplant Recipients With CMV Pneumonia. <i>Journal of Infectious Diseases</i> , 2017, 215, 1514-1522.	4.0	63
288	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1258-1265.	3.9	63

#	ARTICLE	IF	CITATIONS
289	Vitamin A Supplementation and Genital Shedding of Herpes Simplex Virus among HIV-1 Infected Women: A Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 2004, 189, 1466-1471.	4.0	62
290	HIV Infection and Human Herpesvirus-8 Oral Shedding Among Men Who Have Sex with Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 35, 233-238.	2.1	62
291	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
292	CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 258-275.	4.1	62
293	Human Herpesvirus 8: Seroprevalence and Correlates in Prostitutes in Mombasa, Kenya. <i>Journal of Infectious Diseases</i> , 2003, 187, 359-363.	4.0	61
294	Mapping HIV-1 Vaccine Induced T-Cell Responses: Bias towards Less-Conserved Regions and Potential Impact on Vaccine Efficacy in the Step Study. <i>PLoS ONE</i> , 2011, 6, e20479.	2.5	61
295	Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1713-1723.	1.1	60
296	HIV-1 Vaccines and Adaptive Trial Designs. <i>Science Translational Medicine</i> , 2011, 3, 79ps13.	12.4	60
297	Impact of Herpes Simplex Virus Type 2 on HIV-1 Acquisition and Progression in an HIV Vaccine Trial (the Tj ETQq1 1,0.784314 rgBT /C 2.1 60)	2.1	60
298	Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants. <i>Journal of Infectious Diseases</i> , 2016, 214, 36-44.	4.0	60
299	Safety profile of recombinant canarypox HIV vaccines. <i>Vaccine</i> , 2004, 22, 704-713.	3.8	59
300	Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. <i>ELife</i> , 2013, 2, e00288.	6.0	59
301	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1376-1385.	4.0	59
302	Combination prevention for COVID-19. <i>Science</i> , 2020, 368, 551-551.	12.6	59
303	Dynamics of Hepatitis C Virus Replication in Human Liver. <i>American Journal of Pathology</i> , 2003, 163, 433-444.	3.8	58
304	Impact of Corticosteroid Treatment and Antiviral Therapy on Clinical Outcomes in Hematopoietic Cell Transplant Patients Infected with Influenza Virus. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 979-986.	2.0	58
305	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , 2020, 7, e688-e698.	4.7	58
306	Ineffectiveness of Topical Ether for the Treatment of Genital Herpes Simplex Virus Infection. <i>New England Journal of Medicine</i> , 1978, 299, 237-239.	27.0	57

#	ARTICLE	IF	CITATIONS
307	Reinfection is an Uncommon Occurrence in Patients with Symptomatic Recurrent Genital Herpes. <i>Journal of Infectious Diseases</i> , 1984, 149, 645-646.	4.0	57
308	Nosocomial transmission of rotavirus infection. <i>Pediatric Infectious Disease Journal</i> , 1988, 7, 103-108.	2.0	57
309	What Constitutes Efficacy for a Human Immunodeficiency Virus Vaccine that Ameliorates Viremia: Issues Involving Surrogate End Points in Phase 3 Trials. <i>Journal of Infectious Diseases</i> , 2003, 188, 179-193.	4.0	57
310	T Cell Immunity to Herpes Simplex Viruses in Seronegative Subjects: Silent Infection or Acquired Immunity?. <i>Journal of Immunology</i> , 2003, 170, 4380-4388.	0.8	57
311	Herpes Simplex Virus Type 2 and Risk of Intrapartum Human Immunodeficiency Virus Transmission. <i>Obstetrics and Gynecology</i> , 2007, 109, 403-409.	2.4	57
312	Incidence of HIV and sexually transmitted diseases (STD) in a cohort of HIV-negative men who have sex with men (MSM). <i>Aids</i> , 1998, 12, 2041-2048.	2.2	56
313	Risk factors for herpes simplex virus transmission to pregnant women: A couples study. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 1891-1899.	1.3	56
314	Detailed Characterization of T Cell Responses to Herpes Simplex Virus-2 in Immune Seronegative Persons. <i>Journal of Immunology</i> , 2010, 184, 3250-3259.	0.8	56
315	Tolerance and efficacy of recombinant human interferon gamma in the treatment of refractory genital warts. <i>American Journal of Medicine</i> , 1988, 85, 183-188.	1.5	55
316	Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12899-12904.	7.1	55
317	Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. <i>Vaccine</i> , 2009, 27, 243-249.	3.8	55
318	An Effector Phenotype of CD8 ⁺ T Cells at the Junction Epithelium during Clinical Quiescence of Herpes Simplex Virus 2 Infection. <i>Journal of Virology</i> , 2012, 86, 10587-10596.	3.4	55
319	Virologic and Immunologic Evidence of Multifocal Genital Herpes Simplex Virus 2 Infection. <i>Journal of Virology</i> , 2014, 88, 4921-4931.	3.4	55
320	Viral Hepatitis Among Young Men Who Have Sex With Men: Prevalence of Infection, Risk Behaviors, and Vaccination. <i>Sexually Transmitted Diseases</i> , 2003, 30, 425-432.	1.7	54
321	Evasion of the Mucosal Innate Immune System by Herpes Simplex Virus Type 2. <i>Journal of Virology</i> , 2009, 83, 12559-12568.	3.4	54
322	New concepts in understanding genital herpes. <i>Current Infectious Disease Reports</i> , 2009, 11, 457-464.	3.0	54
323	Diversity in CD8 ⁺ T Cell Function and Epitope Breadth Among Persons with Genital Herpes. <i>Journal of Clinical Immunology</i> , 2010, 30, 703-722.	3.8	54
324	The Kinetics of Mucosal Herpes Simplex Virus ² Infection in Humans: Evidence for Rapid Viral-Host Interactions. <i>Journal of Infectious Diseases</i> , 2011, 204, 554-561.	4.0	54

#	ARTICLE	IF	CITATIONS
325	How Does Herpes Simplex Virus Type 2 Influence Human Immunodeficiency Virus Infection and Pathogenesis?. <i>Journal of Infectious Diseases</i> , 2003, 187, 1509-1512.	4.0	53
326	Demographic Factors That Influence the Neutralizing Antibody Response in Recipients of Recombinant HIV-1 gp120 Vaccines. <i>Journal of Infectious Diseases</i> , 2004, 190, 1962-1969.	4.0	53
327	Lower Genitourinary Tract Sources of Seminal HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 41, 430-438.	2.1	53
328	Human Immunodeficiency Virus Vaccine Trials. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007351-a007351.	6.2	53
329	Acquisition of neonatal HSV-1 infection from a paternal source contact. <i>Journal of Pediatrics</i> , 1983, 103, 908-910.	1.8	52
330	Association of Major Histocompatibility Complex Determinants with the Development of Symptomatic and Asymptomatic Genital Herpes Simplex Virus Type 2 Infections. <i>Journal of Infectious Diseases</i> , 1999, 179, 1077-1085.	4.0	52
331	Long Term Persistence of Herpes Simplex Virus-Specific CD8+ CTL in Persons with Frequently Recurring Genital Herpes. <i>Journal of Immunology</i> , 2000, 165, 1146-1152.	0.8	52
332	Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1 Uninfected Adults: AIDS Vaccine Evaluation Group Protocol O22A. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 254-261.	2.1	52
333	Laboratory diagnosis of herpes simplex virus infections. <i>Diagnostic Microbiology and Infectious Disease</i> , 1986, 4, 111S-119S.	1.8	51
334	Immune Responses Elicited by Recombinant Vaccinia-Human Immunodeficiency Virus (HIV) Envelope and HIV Envelope Protein: Analysis of the Durability of Responses and Effect of Repeated Boosting. <i>Journal of Infectious Diseases</i> , 1994, 169, 41-47.	4.0	51
335	Male Genital Tract Compartmentalization of Human Immunodeficiency Virus Type 1 (HIV). <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 561-571.	1.1	51
336	Post-Step modifications for research on HIV vaccines. <i>Aids</i> , 2009, 23, 3-8.	2.2	51
337	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. <i>Lancet, The</i> , 2022, 399, 1141-1153.	13.7	51
338	HSV: persistence in the population: epidemiology, transmission. , 2007, , 656-672.		50
339	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , 2015, 21, 1139-1141.	30.7	50
340	Use of adenovirus type-5 vectored vaccines: a cautionary tale. <i>Lancet, The</i> , 2020, 396, e68-e69.	13.7	50
341	Impact of HIV Infection and Kaposi Sarcoma on Human Herpesvirus-8 Mucosal Replication and Dissemination in Uganda. <i>PLoS ONE</i> , 2009, 4, e4222.	2.5	50
342	Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. <i>Journal of Experimental Medicine</i> , 2017, 214, 2315-2329.	8.5	49

#	ARTICLE	IF	CITATIONS
343	Broadly Neutralizing Antibodies for HIV Prevention. Annual Review of Medicine, 2020, 71, 329-346.	12.2	49
344	Spectrum of rectal biopsy abnormalities in homosexual men with intestinal symptoms. Gastroenterology, 1986, 91, 651-659.	1.3	48
345	Absence of Detectable Human Herpesvirus 8 in the Semen of Human Immunodeficiency Virus-Infected Men without Kaposi's Sarcoma. Journal of Infectious Diseases, 1997, 176, 775-777.	4.0	48
346	Use of the MagNA Pure LC Automated Nucleic Acid Extraction System followed by Real-Time Reverse Transcription-PCR for Ultrasensitive Quantitation of Hepatitis C Virus RNA. Journal of Clinical Microbiology, 2004, 42, 4130-4136.	3.9	48
347	Antimicrobial Resistance Prevention Initiative—An Update: Proceedings of an Expert Panel on Resistance. American Journal of Medicine, 2007, 120, S4-S25.	1.5	48
348	A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine, 2011, 29, 1948-1958.	3.8	48
349	H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients. Emerging Infectious Diseases, 2011, 17, 653-660.	4.3	48
350	Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell Recipients. Biology of Blood and Marrow Transplantation, 2012, 18, 1391-1400.	2.0	48
351	Antigen-Specific T Cells Localize to the Uterine Cervix in Women with Genital Herpes Simplex Virus Type 2 Infection. Journal of Infectious Diseases, 2000, 182, 662-670.	4.0	47
352	Repeat-Region Polymorphisms in the Gene for the Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin-Related Molecule: Effects on HIV-1 Susceptibility. Journal of Infectious Diseases, 2006, 193, 698-702.	4.0	47
353	Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica, 2011, 96, 1838-1845.	3.5	47
354	HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13492-13497.	7.1	47
355	Plasma Cytokine Levels and Risk of HIV Type 1 (HIV-1) Transmission and Acquisition: A Nested Case-Control Study Among HIV-1-Serodiscordant Couples. Journal of Infectious Diseases, 2015, 211, 1451-1460.	4.0	47
356	Plasma and Cerebrospinal Fluid Herpes Simplex Virus Levels at Diagnosis and Outcome of Neonatal Infection. Journal of Pediatrics, 2015, 166, 827-833.	1.8	47
357	Transient Oral Human Cytomegalovirus Infections Indicate Inefficient Viral Spread from Very Few Initially Infected Cells. Journal of Virology, 2017, 91, .	3.4	47
358	Prevalence and Incidence of Herpesvirus Infections Among Homosexually Active Men. Journal of Infectious Diseases, 1984, 149, 1026-1027.	4.0	46
359	Clinical Course of Patients With Serologic Evidence of Recurrent Genital Herpes Presenting With Signs and Symptoms of First Episode Disease. Sexually Transmitted Diseases, 1999, 26, 221-225.	1.7	46
360	Evaluation of Real-Time PCR versus PCR with Liquid-Phase Hybridization for Detection of Enterovirus RNA in Cerebrospinal Fluid. Journal of Clinical Microbiology, 2003, 41, 3133-3141.	3.9	46

#	ARTICLE	IF	CITATIONS
361	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	46
362	First-episode, recurrent, and asymptomatic herpes simplex infections. <i>Journal of the American Academy of Dermatology</i> , 1988, 18, 169-172.	1.2	45
363	Acute Infection of <i>Macaca nemestrina</i> by Human Immunodeficiency Virus Type 1. <i>Virology</i> , 1993, 195, 422-431.	2.4	45
364	Oral Herpes Simplex Virus Type 2 Reactivation in HIV-Positive and -Negative Men. <i>Journal of Infectious Diseases</i> , 2006, 194, 420-427.	4.0	45
365	HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. <i>Aids</i> , 2009, 23, 479-483.	2.2	45
366	Daily Acyclovir to Decrease Herpes Simplex Virus Type 2 (HSV-2) Transmission from HSV-2/HIV-1 Coinfected Persons: A Randomized Controlled Trial. <i>Journal of Infectious Diseases</i> , 2013, 208, 1366-1374.	4.0	45
367	Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. <i>Mucosal Immunology</i> , 2017, 10, 1259-1269.	6.0	45
368	A comparison of between detailed and simple histories in the diagnosis of genital herpes complicating pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 172, 1299-1303.	1.3	44
369	Challenges in Genital Herpes Simplex Virus Management. <i>Journal of Infectious Diseases</i> , 2002, 186, S29-S33.	4.0	44
370	HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. <i>Blood</i> , 2011, 117, 5391-5402.	1.4	44
371	The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet, The</i> , 2020, 395, 384-388.	13.7	44
372	Gender Differences in Clinical Presentation and Outcomes of Epidemic Kaposi Sarcoma in Uganda. <i>PLoS ONE</i> , 2010, 5, e13936.	2.5	44
373	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. <i>Scientific Reports</i> , 2021, 11, 23921.	3.3	44
374	Transmission of herpes simplex virus from father to neonate. <i>Journal of Pediatrics</i> , 1983, 103, 905-907.	1.8	43
375	HIV-1MN Recombinant Glycoprotein 160 Vaccine-Induced Cellular and Humoral Immunity Boosted by HIV-1MN Recombinant Glycoprotein 120 Vaccine. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 115-132.	1.1	43
376	Herpes Simplex Inhibits the Capacity of Lymphoblastoid B Cell Lines to Stimulate CD4+T Cells. <i>Journal of Immunology</i> , 2001, 166, 6242-6249.	0.8	43
377	Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. <i>MAbs</i> , 2017, 9, 792-800.	5.2	43
378	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , the, 2019, 6, e737-e749.	4.7	43

#	ARTICLE	IF	CITATIONS
379	HBs Ag-Negative Hepatitis in a Hemodialysis Unit. <i>New England Journal of Medicine</i> , 1975, 293, 1273-1278.	27.0	42
380	Influenza Viral RNA Detection in Blood as a Marker to Predict Disease Severity in Hematopoietic Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2012, 206, 1872-1877.	4.0	42
381	Rapid Viral Expansion and Short Drug Half-Life Explain the Incomplete Effectiveness of Current Herpes Simplex Virus 2-Directed Antiviral Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5820-5829.	3.2	42
382	Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. <i>American Journal of Obstetrics and Gynecology</i> , 1997, 177, 450-454.	1.3	41
383	Virological and Immunological Effects of Combination Antiretroviral Therapy with Zidovudine, Lamivudine, and Indinavir during Primary Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2000, 182, 950-954.	4.0	41
384	Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 136-148.	2.0	41
385	Abacavir hypersensitivity reaction in primary HIV infection. <i>Aids</i> , 2006, 20, 1269-1274.	2.2	41
386	HHV-8 infection: a model for reactivation and transmission. <i>Reviews in Medical Virology</i> , 2002, 12, 47-63.	8.3	40
387	Reduced Levels of Neutralizing Antibodies to Kaposi Sarcoma-associated Herpesvirus in Persons with a History of Kaposi Sarcoma. <i>Journal of Infectious Diseases</i> , 2004, 189, 2016-2022.	4.0	40
388	Adolescents Are More Likely to Develop Posttransplant Lymphoproliferative Disorder After Primary Epstein-Barr Virus Infection Than Younger Renal Transplant Recipients. <i>Transplantation</i> , 2007, 83, 1423-1428.	1.0	40
389	Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 2903-2919.	8.2	40
390	Cytomegalovirus Viremia as a Risk Factor for Mortality Prior to Antiretroviral Therapy among HIV-Infected Gold Miners in South Africa. <i>PLoS ONE</i> , 2011, 6, e25571.	2.5	40
391	Therapy for Human Immunodeficiency Virus Infection – What Have We Learned?. <i>New England Journal of Medicine</i> , 1996, 335, 1142-1144.	27.0	39
392	Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type 1. <i>American Journal of Obstetrics and Gynecology</i> , 2000, 183, 948-955.	1.3	39
393	Continued evolution of HIV-1 circulating in blood monocytes with antiretroviral therapy: genetic analysis of HIV-1 in monocytes and CD4+ T cells of patients with discontinued therapy. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1118-1126.	3.3	39
394	Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2007, 86, 523-529.	2.8	39
395	HIV-1 Vaccine-Induced T-Cell Responses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1. <i>PLoS Pathogens</i> , 2013, 9, e1003404.	4.7	39
396	Risk of Recurrence after Treatment of First-episode Genital Herpes with Intravenous Acyclovir. <i>Sexually Transmitted Diseases</i> , 1985, 12, 215-218.	1.7	38

#	ARTICLE	IF	CITATIONS
397	Association between Cytomegalovirus Seroconversion and Upper Genital Tract Infection among Women Attending a Sexually Transmitted Disease Clinic: A Prospective Study. <i>Journal of Infectious Diseases</i> , 1998, 177, 1188-1193.	4.0	38
398	Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor β chain repertoire and reduces the level of T-cell oligoclonality. <i>Blood</i> , 2000, 95, 1743-1751.	1.4	38
399	How Many Human Immunodeficiency Virus Type 1-Infected Target Cells Can a Cytotoxic T-Lymphocyte Kill?. <i>Journal of Virology</i> , 2005, 79, 13579-13586.	3.4	38
400	$\gamma\delta$ T Cells Involvement in Viral Immune Control of Chronic Human Herpesvirus 8 Infection. <i>Journal of Immunology</i> , 2008, 180, 3417-3425.	0.8	38
401	Rapidly Cleared Episodes of Oral and Anogenital Herpes Simplex Virus Shedding in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 482-488.	2.1	38
402	Herpes simplex virus type 2 detection by culture and polymerase chain reaction and relationship to genital symptoms and cervical antibody status during the third trimester of pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 1997, 176, 443-451.	1.3	37
403	Outbreak of <i>Stenotrophomonas maltophilia</i> Bacteremia Among Patients Undergoing Bone Marrow Transplantation: Association With Faulty Replacement of Handwashing Soap. <i>Infection Control and Hospital Epidemiology</i> , 1999, 20, 756-758.	1.8	37
404	Early Induction and Maintenance of Env-Specific T-Helper Cells following Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2003, 77, 2663-2674.	3.4	37
405	Neonatal Herpes Should be a Reportable Disease. <i>Sexually Transmitted Diseases</i> , 2005, 32, 521-525.	1.7	37
406	Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. <i>Sexually Transmitted Infections</i> , 2007, 83, 359-364.	1.9	37
407	Antimicrobial resistance prevention initiative—an update: Proceedings of an expert panel on resistance. <i>American Journal of Infection Control</i> , 2007, 35, S1-S23.	2.3	37
408	Introduction of a novel parechovirus RT-PCR clinical test in a regional medical center. <i>Journal of Clinical Virology</i> , 2011, 51, 50-53.	3.1	37
409	A Prospective Study of Hormonal Contraceptive Use and Cervical Shedding of Herpes Simplex Virus in Human Immunodeficiency Virus Type 1-Seropositive Women. <i>Journal of Infectious Diseases</i> , 2002, 185, 1822-1825.	4.0	36
410	Population Level Impact of an Imperfect Prophylactic Vaccine for Herpes Simplex Virus-2. <i>Sexually Transmitted Diseases</i> , 2010, 37, 290-297.	1.7	36
411	An Important Role for Major Histocompatibility Complex Class I-Restricted T Cells, and a Limited Role for Gamma Interferon, in Protection of Mice against Lethal Herpes Simplex Virus Infection. <i>Journal of Virology</i> , 1999, 73, 2058-2063.	3.4	36
412	Frequency and reactivation of nongenital lesions among patients with genital herpes simplex virus. <i>American Journal of Medicine</i> , 1995, 98, 237-242.	1.5	35
413	Herpes Simplex Virus Shedding among Human Immunodeficiency Virus -Negative Men Who Have Sex with Men: Site and Frequency of Shedding. <i>Journal of Infectious Diseases</i> , 1998, 178, 978-982.	4.0	35
414	Detection of Herpes Simplex Virus DNA in Semen of Men With Genital HSV-2 Infection. <i>Sexually Transmitted Diseases</i> , 1999, 26, 1-3.	1.7	35

#	ARTICLE	IF	CITATIONS
415	Blood Monocytes Harbor HIV Type 1 Strains with Diversified Phenotypes Including Macrophage-Specific CCR5 Virus. <i>Journal of Infectious Diseases</i> , 2008, 197, 309-318.	4.0	35
416	CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	35
417	Provision of treatment in HIV-1 vaccine trials in developing countries. <i>Lancet</i> , The, 2003, 362, 993-994.	13.7	34
418	Inhibition of MHC Class I Is a Virulence Factor in Herpes Simplex Virus Infection of Mice. <i>PLoS Pathogens</i> , 2005, 1, e7.	4.7	34
419	Rapid Detection Directly from Patient Serum Samples of Human Cytomegalovirus UL97 Mutations Conferring Ganciclovir Resistance. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2681-2683.	3.9	34
420	Independent and Cooperative Antiviral Actions of Beta Interferon and Gamma Interferon against Herpes Simplex Virus Replication in Primary Human Fibroblasts. <i>Journal of Virology</i> , 2008, 82, 1934-1945.	3.4	34
421	WU and KI Polyomaviruses in Respiratory Samples from Allogeneic Hematopoietic Cell Transplant Recipients. <i>Emerging Infectious Diseases</i> , 2012, 18, 1580-1588.	4.3	34
422	Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. <i>Vaccine</i> , 2015, 33, 2347-2353.	3.8	34
423	Valganciclovir for the Suppression of Epstein-Barr Virus Replication. <i>Journal of Infectious Diseases</i> , 2017, 216, 198-202.	4.0	34
424	Evidence for Limited Genetic Compartmentalization of HIV-1 between Lung and Blood. <i>PLoS ONE</i> , 2009, 4, e6949.	2.5	34
425	Seroepidemiology of Human Herpesvirus 8 Among Young Men Who Have Sex With Men. <i>Sexually Transmitted Diseases</i> , 2001, 28, 176-183.	1.7	33
426	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 ⁺ T-Cell Responses by Interleukin-12 Plasmid DNA. <i>Vaccine Journal</i> , 2017, 24, .	3.1	33
427	Cervical shedding of cytomegalovirus in human immunodeficiency virus type 1-infected women. <i>Journal of Medical Virology</i> , 1999, 59, 469-473.	5.0	32
428	Acyclovir Sensitivity of Sequential Herpes Simplex Virus Type 2 Isolates from the Genital Mucosa of Immunocompetent Women. <i>Journal of Infectious Diseases</i> , 2005, 192, 1102-1107.	4.0	32
429	Herpes Simplex Virus Type 2 and HIV-1: The Dialogue between the 2 Organisms Continues. <i>Journal of Infectious Diseases</i> , 2007, 195, 1242-1244.	4.0	32
430	Successful Modification of a pp65 Antigenemia-Based Early Treatment Strategy for Prevention of Cytomegalovirus Disease in Allogeneic Marrow Transplant Recipients. <i>Blood</i> , 1999, 93, 1781-1782.	1.4	32
431	Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: Relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. , 1999, 58, 165-173.		31
432	Assessment of a Combined Testing Strategy for Detection of Antibodies to Human Herpesvirus 8 (HHV-8) in Persons with Kaposi's Sarcoma, Persons with Asymptomatic HHV-8 Infection, and Persons at Low Risk for HHV-8 Infection. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3822-3825.	3.9	31

#	ARTICLE	IF	CITATIONS
433	Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 123, 662-670.	2.5	31
434	Penile Intraepithelial Neoplasia: Clinical Presentation and an Analysis of the Physical State of Human Papillomavirus DNA. <i>Journal of Infectious Diseases</i> , 1993, 168, 38-46.	4.0	30
435	Development of multiplexed real-time quantitative polymerase chain reaction assay for detecting human adenoviruses. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 263-271.	1.8	30
436	In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques. <i>Retrovirology</i> , 2010, 7, 12.	2.0	30
437	Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2593-2600.	3.0	30
438	MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load. <i>PLoS ONE</i> , 2012, 7, e43396.	2.5	30
439	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , 2015, 10, e0137666.	2.5	30
440	Serial in Vivo Passage of HIV-1 Infection in <i>Macaca nemestrina</i> . <i>Virology</i> , 1997, 238, 336-343.	2.4	29
441	Primary human herpesvirus-6 associated with an afebrile seizure in a 3-week-old infant. <i>Journal of Medical Virology</i> , 2002, 66, 384-387.	5.0	29
442	Overlapping Reactivations of Herpes Simplex Virus Type 2 in the Genital and Perianal Mucosa. <i>Journal of Infectious Diseases</i> , 2010, 201, 499-504.	4.0	29
443	Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes. <i>Science Translational Medicine</i> , 2016, 8, 324ra15.	12.4	29
444	Evaluation of New Anti-Infective Drugs for the Treatment of Uncomplicated Gonorrhea in Adults and Adolescents. <i>Clinical Infectious Diseases</i> , 1992, 15, S123-S130.	5.8	28
445	Underestimation of HSV-2 Seroprevalence in a High-risk Population by Microneutralization Assay. <i>Sexually Transmitted Diseases</i> , 1993, 20, 230-235.	1.7	28
446	Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. <i>Vaccine</i> , 1998, 16, 493-506.	3.8	28
447	Rapid Polymerase Chain Reaction Assay to Detect Herpes Simplex Virus in the Genital Tract of Women in Labor. <i>Obstetrics and Gynecology</i> , 2010, 115, 1209-1216.	2.4	28
448	Image analysis for accurately counting CD4+ and CD8+ T cells in human tissue. <i>Journal of Virological Methods</i> , 2015, 222, 117-121.	2.1	28
449	Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 627-631.	2.0	28
450	Clinical and Virologic Efficacy of Herpes Simplex Virus Type 2 Suppression by Acyclovir in a Multicontinent Clinical Trial. <i>Journal of Infectious Diseases</i> , 2010, 201, 1164-1168.	4.0	27

#	ARTICLE	IF	CITATIONS
451	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	8.4	27
452	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	2.5	27
453	Historical Findings in Subjects from a High Socioeconomic Group Who Have Genital Infections with Herpes Simplex Virus. <i>Sexually Transmitted Diseases</i> , 1982, 9, 15-20.	1.7	26
454	Raising the Consciousness for Identifying and Controlling Viral STDs. <i>Sexually Transmitted Diseases</i> , 1998, 25, 58-69.	1.7	26
455	High Serum Hepatitis C Virus (HCV) RNA Load Predicts the Presence of HCV RNA in Saliva from Individuals with Chronic and Acute HCV Infection. <i>Journal of Infectious Diseases</i> , 2006, 193, 672-676.	4.0	26
456	HIV-1 CTL-Based Vaccine Immunogen Selection: Antigen Diversity and Cellular Response Features. <i>Current HIV Research</i> , 2007, 5, 97-107.	0.5	26
457	Hepatitis C Virus Is Infrequently Evaluated and Treated in an Urban HIV Clinic Population. <i>AIDS Patient Care and STDs</i> , 2009, 23, 925-929.	2.5	26
458	Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. <i>Aids</i> , 2011, 25, 153-158.	2.2	26
459	Herpes simplex viral pneumonitis in childhood. <i>Journal of Pediatrics</i> , 1984, 104, 211-215.	1.8	25
460	Human herpesvirus 6 infection in febrile infants ninety days of age and younger. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 996-999.	2.0	25
461	Most DC-SIGNR transcripts at mucosal HIV transmission sites are alternatively spliced isoforms. <i>European Journal of Human Genetics</i> , 2005, 13, 707-715.	2.8	25
462	HIV vaccines: mosaic approach to virus diversity. <i>Nature Medicine</i> , 2010, 16, 268-270.	30.7	25
463	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2741.	4.8	25
464	Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 16–April 16, 2020. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2334.	7.4	25
465	A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 680-687.	2.1	25
466	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. <i>JCI Insight</i> , 2020, 5, .	5.0	25
467	Differential effect of systemic acyclovir treatment of genital HSV-2 infections on antibody responses to individual HSV-2 proteins. <i>Journal of Medical Virology</i> , 1988, 24, 309-320.	5.0	24
468	Respiratory Failure Caused by 2009 Novel Influenza A/H1N1 in a Hematopoietic Stem-Cell Transplant Recipient: Detection of Extrapulmonary H1N1 RNA and Use of Intravenous Peramivir. <i>Annals of Internal Medicine</i> , 2010, 152, 619.	3.9	24

#	ARTICLE	IF	CITATIONS
469	Self-Collection of Foam Nasal Swabs for Respiratory Virus Detection by PCR among Immunocompetent Subjects and Hematopoietic Cell Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2013, 51, 324-327.	3.9	24
470	Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. <i>Journal of Clinical Virology</i> , 2014, 60, 127-132.	3.1	24
471	Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. <i>Vaccine Journal</i> , 2016, 23, 496-506.	3.1	24
472	Dynamics of Persistent Oral Cytomegalovirus Shedding During Primary Infection in Ugandan Infants. <i>Journal of Infectious Diseases</i> , 2016, 214, 1735-1743.	4.0	24
473	Poor Correlation Between Genital Lesions and Detection of Herpes Simplex Virus in Women in Labor. <i>Obstetrics and Gynecology</i> , 2005, 106, 268-274.	2.4	23
474	A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. <i>Statistical Communications in Infectious Diseases</i> , 2011, 3, .	0.2	23
475	Changes in the Soluble Mucosal Immune Environment During Genital Herpes Outbreaks. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 194-202.	2.1	23
476	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	2.5	23
477	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 645-656.	1.1	23
478	ENDEMIC SPREAD OF HERPES SIMPLEX VIRUS TYPE 1 AMONG ADOLESCENT WRESTLERS AND THEIR COACHES. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 1108-1109.	2.0	23
479	Dual infection with human papillomavirus in a population with overt genital condylomas. <i>Journal of the American Academy of Dermatology</i> , 1993, 28, 434-442.	1.2	22
480	Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 195, 115-120.	1.3	22
481	Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. <i>Journal of Medical Virology</i> , 2011, 83, 1696-1703.	5.0	22
482	Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination. <i>PLoS ONE</i> , 2012, 7, e33969.	2.5	22
483	A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens. <i>Journal of Virology</i> , 2015, 89, 8497-8509.	3.4	22
484	Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. <i>Journal of Infectious Diseases</i> , 2018, 218, 1691-1699.	4.0	22
485	Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa. <i>PLoS ONE</i> , 2016, 11, e0155124.	2.5	22
486	Perspectives on Switching Oral Acyclovir from Prescription to Over-the-Counter Status: Report of a Consensus Panel. <i>Clinical Infectious Diseases</i> , 1998, 26, 659-663.	5.8	21

#	ARTICLE	IF	CITATIONS
487	Herpes Simplex Virus Shedding and Plasma Human Immunodeficiency Virus RNA Levels in Coinfected Women. <i>Clinical Infectious Diseases</i> , 2001, 33, 885-890.	5.8	21
488	Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines" Vaccine, 2014, 32, 1561-1562.	3.8	21
489	Serum Neutralizing Antibody After Rabies Postexposure Prophylaxis. <i>Annals of Internal Medicine</i> , 1976, 85, 170.	3.9	20
490	Atypical Generalized Zoster with Lymphadenitis Mimicking Lymphoma. <i>New England Journal of Medicine</i> , 1980, 302, 848-851.	27.0	20
491	A Randomized, Double-Blind, Phase I/II Trial of Tumor Necrosis Factor and Interferon-Gamma for Treatment of AIDS-Related Complex (Protocol 025 from the AIDS Clinical Trials Group). <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 581-587.	1.1	20
492	Gram-negative bloodstream infections in hematopoietic stem cell transplant patients: The roles of needleless device use, bathing practices, and catheter care. <i>American Journal of Infection Control</i> , 2009, 37, 327-334.	2.3	20
493	No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy. <i>Journal of Infectious Diseases</i> , 2016, 214, 258-264.	4.0	20
494	Human Herpesvirus 6B and Lower Respiratory Tract Disease After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2019, 37, 2670-2681.	1.6	20
495	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Computational Biology</i> , 2020, 16, e1007626.	3.2	20
496	Estimating the Risk of Human Herpesvirus 6 and Cytomegalovirus Transmission to Ugandan Infants from Viral Shedding in Saliva by Household Contacts. <i>Viruses</i> , 2020, 12, 171.	3.3	20
497	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003868.	8.4	20
498	Calibration Curves for Real-Time PCR. <i>Clinical Chemistry</i> , 2005, 51, 1132-1136.	3.2	19
499	Acyclovir Achieves a Lower Concentration in African HIV-Seronegative, Herpes Simplex Virus 2-Seropositive Women than in Non-African Populations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2777-2779.	3.2	19
500	A Fixed Spatial Structure of CD8+ T Cells in Tissue during Chronic HSV-2 Infection. <i>Journal of Immunology</i> , 2018, 201, 1522-1535.	0.8	19
501	Stigma, Implicit Bias, and Long-Lasting Prevention Interventions to End the Domestic HIV/AIDS Epidemic. <i>American Journal of Public Health</i> , 2020, 110, 67-68.	2.7	19
502	Unintegrated Circular HIV-1 DNA in the Peripheral Mononuclear Cells of HIV-1-Infected Subjects: Association With High Levels of Plasma HIV-1 RNA, Rapid Decline in CD4 Count, and Clinical Progression to AIDS. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 17, 303-313.	0.3	19
503	Analysis of Cytotoxic T Lymphocyte Responses to SIV Proteins in SIV-Infected Macaques Using Antigen-Specific Stimulation with Recombinant Vaccinia and Fowl Poxviruses. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 551-560.	1.1	18
504	Genital HSV Detection among HIV-1-Infected Pregnant Women in Labor. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2011, 2011, 1-4.	1.5	18

#	ARTICLE	IF	CITATIONS
505	Herpes Simplex Virus Type 2 Suppressive Therapy with Acyclovir or Valacyclovir Does Not Select for Specific HIV-1 Resistance in HIV-1/HSV-2 Dually Infected Persons. <i>Journal of Infectious Diseases</i> , 2011, 203, 117-121.	4.0	18
506	High-Dose Valacyclovir Decreases Plasma HIV-1 RNA More Than Standard-Dose Acyclovir in Persons Coinfected with HIV-1 and HSV-2. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 201-208.	2.1	18
507	Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children. <i>Scientific Reports</i> , 2017, 7, 13105.	3.3	18
508	Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, 1534-1540.	4.0	18
509	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	18
510	Frequent Genital HSV-2 Shedding among Women during Labor in Soweto, South Africa. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2014, 2014, 1-8.	1.5	17
511	HVTN 097: Evaluation of the RV144 Vaccine Regimen in HIV Uninfected South African Adults. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A33-A34.	1.1	17
512	In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation. <i>Journal of Infectious Diseases</i> , 2016, 214, 23-31.	4.0	17
513	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	3.3	17
514	Herpes Simplex Virus. , 2015, , 1713-1730.e6.		17
515	Treatment of HIV Infection – Progress in Perspective. <i>New England Journal of Medicine</i> , 1992, 326, 484-486.	27.0	16
516	Evaluation of New Anti-Infective Drugs for the Treatment of Syphilis. <i>Clinical Infectious Diseases</i> , 1992, 15, S140-S147.	5.8	16
517	Sequence-Based Methods for Identifying Epidemiologically Linked Herpes Simplex Virus Type 2 Strains. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2541-2546.	3.9	16
518	HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. <i>Clinical Investigation</i> , 2012, 2, 245-254.	0.0	16
519	An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa232.	0.9	16
520	Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 671-679.	2.1	16
521	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , 2016, 11, e0161753.	2.5	16
522	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	2.5	16

#	ARTICLE	IF	CITATIONS
523	Broadly neutralizing monoclonal antibodies for HIV prevention. <i>Journal of the International AIDS Society</i> , 2021, 24, e25829.	3.0	16
524	Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney. <i>Aids</i> , 2000, 14, 375-381.	2.2	15
525	Search for Polymorphisms in the Genes for Herpesvirus Entry Mediator, Nectin1, and Nectin2 in Immune Seronegative Individuals. <i>Journal of Infectious Diseases</i> , 2002, 185, 36-44.	4.0	15
526	Concordance Between HIV Source Partner Identification and Molecular Confirmation in Acute Retroviral Syndrome. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 232-243.	2.1	15
527	Human Herpesvirus 8 Infection Among Adolescents in the REACH Cohort. <i>JAMA Pediatrics</i> , 2006, 160, 937-42.	3.0	15
528	Successful Isolation of Infectious and High Titer Human Monocyte-Derived HIV-1 from Two Subjects with Discontinued Therapy. <i>PLoS ONE</i> , 2013, 8, e65071.	2.5	15
529	A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial. <i>Vaccine</i> , 2016, 34, 5792-5801.	3.8	15
530	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. <i>Clinical Infectious Diseases</i> , 2020, 72, 50-60.	5.8	15
531	Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. <i>Clinical Infectious Diseases</i> , 2020, 73, 1540-1544.	5.8	15
532	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	3.9	15
533	Tissue-Resident-Memory CD8+ T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital Herpes. <i>Frontiers in Immunology</i> , 2021, 12, 735643.	4.8	15
534	Lack of Effect on Survival of High-Dose Acyclovir and Zidovudine Compared with Zidovudine Alone for Acquired Immunodeficiency Syndrome. <i>Antiviral Therapy</i> , 1998, 3, 25-32.	1.0	15
535	Do Scarce Targets or T Killers Control Primary HIV Infection?. <i>Journal of Theoretical Biology</i> , 2002, 214, 209-214.	1.7	14
536	Correlates of Human Herpesvirus-8 Seropositivity Among U.S. Military Members Recently Infected With Human Immunodeficiency Virus. <i>Sexually Transmitted Diseases</i> , 2003, 30, 713-718.	1.7	14
537	Longitudinal Analysis of Herpes Simplex Virus-Specific CD4+Cell Clonotypes in Infected Tissues and Blood. <i>Journal of Infectious Diseases</i> , 2005, 191, 2012-2021.	4.0	14
538	Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. <i>EBioMedicine</i> , 2015, 2, 2062-2069.	6.1	14
539	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. <i>Current Opinion in Virology</i> , 2016, 17, 57-65.	5.4	14
540	Preventing acquisition of HIV is the only path to an AIDS-free generation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3798-3800.	7.1	14

#	ARTICLE	IF	CITATIONS
541	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , 2021, 64, 103203.	6.1	14
542	B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	14
543	Does Frequency of Genital Herpes Recurrences Predict Risk of Transmission? Further Analysis of the Valacyclovir Transmission Study. <i>Sexually Transmitted Diseases</i> , 2008, 35, 124-128.	1.7	13
544	Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda. <i>Journal of Infectious Diseases</i> , 2016, 213, 439-447.	4.0	13
545	A selective defect in tissue factor mRNA expression in monocytes from AIDS patients. <i>Clinical Immunology and Immunopathology</i> , 1990, 54, 1-13.	2.0	12
546	Evaluation of New Anti-Infective Drugs for the Treatment of Vaginal Infections. <i>Clinical Infectious Diseases</i> , 1992, 15, S115-S122.	5.8	12
547	A randomized, double-blind trial of parenteral low dose versus high dose interferon- β in combination with cryotherapy for treatment of condyloma acuminatum. <i>Antiviral Research</i> , 1997, 35, 41-52.	4.1	12
548	Comparison of assays to detect cytomegalovirus shedding in the semen of HIV-infected men. <i>Journal of Virological Methods</i> , 2000, 90, 185-191.	2.1	12
549	Persistence of low levels of simian immunodeficiency virus in macaques that were transiently viremic by conventional testing. <i>Virology</i> , 2004, 323, 208-219.	2.4	12
550	Polymerase chain reaction diagnosis of primary human herpesvirus-6 infection in the acute care setting. <i>Journal of Pediatrics</i> , 2006, 149, 480-485.	1.8	12
551	Uptake of Male Circumcision in an HIV Vaccine Efficacy Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 108-110.	2.1	12
552	Frequent Detection of Human Adenovirus from the Lower Gastrointestinal Tract in Men Who Have Sex with Men. <i>PLoS ONE</i> , 2010, 5, e11321.	2.5	12
553	Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2. <i>Vaccine</i> , 2011, 29, 7058-7066.	3.8	12
554	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. <i>PLoS ONE</i> , 2017, 12, e0176428.	2.5	12
555	Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons. <i>Aids</i> , 2018, 32, 2525-2531.	2.2	12
556	Patient-initiated therapy for recurrent genital herpetic infections. <i>American Journal of Medicine</i> , 1982, 73, 342-346.	1.5	11
557	The Natural History of HIV Infection: Implications for the Assessment of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 1993, 16, S2-S6.	5.8	11
558	HIV-Infected Macrophages as Efficient Stimulator Cells for Detection of Cytotoxic T Cell Responses to HIV in Seronegative and Seropositive Vaccine Recipients. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 541-549.	1.1	11

#	ARTICLE	IF	CITATIONS
559	Herpes Simplex Virus-associated Sepsis in a Previously Infected Immunocompetent Adult. <i>Annals of Internal Medicine</i> , 2003, 139, 153.	3.9	11
560	Preinfection Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T Lymphocytes Failed To Prevent HIV Type 1 Infection from Strains Genetically Unrelated to Viruses in Long-Term Exposed Partners. <i>Journal of Virology</i> , 2009, 83, 10821-10829.	3.4	11
561	A Prospective Cohort Study of Partner Testing for Herpes Simplex Virus and Sexual Behavior During Pregnancy. <i>Journal of Infectious Diseases</i> , 2012, 206, 486-494.	4.0	11
562	Broadly neutralizing antibodies to prevent HIV-1. <i>Science</i> , 2017, 358, 46-47.	12.6	11
563	Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques. <i>Journal of Virology</i> , 2019, 93, .	3.4	11
564	Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP ² DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults. <i>Vaccines</i> , 2020, 8, 741.	4.4	11
565	Genital Herpes Simplex Virus Infections in Adults. <i>Urologic Clinics of North America</i> , 1984, 11, 103-119.	1.8	11
566	Analysis of the HIV Vaccine Trials Network 702 Phase 2b HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	4.0	11
567	CD4+ T cell receptor repertoire perturbations in HIV-1 infection: Association with plasma viremia and disease progression. <i>Clinical Immunology</i> , 2006, 119, 95-102.	3.2	10
568	Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. <i>Vaccine Journal</i> , 2014, 21, 1589-1599.	3.1	10
569	Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)-Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2 Coinfected Individuals. <i>Journal of Infectious Diseases</i> , 2016, 213, 1573-1578.	4.0	10
570	Distinct populations of antigen specific tissue resident CD8 T cells in human cervix mucosa. <i>JCI Insight</i> , 2021, 6, .	5.0	10
571	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , 2021, 13, 1921.	3.3	10
572	Analysis of a major target of the human immune response to cytomegalovirus using monoclonal antibodies. <i>Journal of Medical Virology</i> , 1988, 25, 237-243.	5.0	9
573	Herpes Simplex Type 2 Infection in the Developing World. <i>Sexually Transmitted Diseases</i> , 2000, 27, 30-31.	1.7	9
574	Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads. <i>PLoS Computational Biology</i> , 2021, 17, e1009072.	3.2	9
575	Subclinical Shedding of HSV: Its Potential for Reduction by Antiviral Therapy. <i>Advances in Experimental Medicine and Biology</i> , 1996, 394, 11-16.	1.6	9
576	Prevention of herpes simplex virus type 2 transmission with antiviral therapy. <i>Herpes: the Journal of the IHMF</i> , 2004, 11 Suppl 3, 170A-174A.	0.3	9

#	ARTICLE	IF	CITATIONS
577	Neonatal herpes simplex virus infection. <i>Pediatric Infectious Disease Journal</i> , 1987, 6, 1057-1061.	2.0	8
578	Potential Benefits of a Serodiagnostic Test for Herpes Simplex Virus Type 1 (HSV-1) to Prevent Neonatal HSV-1 Infection. <i>Sexually Transmitted Diseases</i> , 2002, 29, 399-405.	1.7	8
579	Adoptive Immunotherapy of Viral Infections: Should Infectious Disease Embrace Cellular Immunotherapy?. <i>Journal of Infectious Diseases</i> , 2017, 216, 926-928.	4.0	8
580	Expanding Efforts and Support to Respond to the HIV and COVID-19 Intersecting Pandemics. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1227.	7.4	8
581	Evaluation of New Anti-Infective Drugs for the Treatment of Chancroid. <i>Clinical Infectious Diseases</i> , 1992, 15, S108-S114.	5.8	7
582	Towards prediction of degenerate CTL epitope recognition. <i>Hum Vaccin</i> , 2008, 4, 115-120.	2.4	7
583	Detection of Adeno-Associated Virus Viremia in Hematopoietic Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2011, 204, 1746-1749.	4.0	7
584	Nuclear factor kappa B is required for the production of infectious human herpesvirus 8 virions. <i>Frontiers in Microbiology</i> , 2014, 5, 129.	3.5	7
585	Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition. <i>Sexually Transmitted Infections</i> , 2018, 94, 568-570.	1.9	7
586	Treatment of Herpes Simplex Virus Infections. <i>Clinics in Laboratory Medicine</i> , 1987, 7, 815-829.	1.4	6
587	Clinical Studies with Herpes Simplex Virus Type 2 Curtis Strain Vaccine. <i>Clinical Infectious Diseases</i> , 1991, 13, S904-S905.	5.8	6
588	A Reduced Dose of Zidovudine in Patients with AIDS. <i>New England Journal of Medicine</i> , 1991, 324, 994-996.	27.0	6
589	Evaluation of New Anti-Infective Drugs for the Treatment of Sexually Transmitted Chlamydial Infections and Related Clinical Syndromes. <i>Clinical Infectious Diseases</i> , 1992, 15, S131-S139.	5.8	6
590	Evaluation of New Anti-Infective Drugs for the Treatment of Genital Infections Due to Herpes Simplex Virus. <i>Clinical Infectious Diseases</i> , 1992, 15, S99-S107.	5.8	6
591	Safety, Pharmacokinetics, and Antiviral Response of CD4-Immunoglobulin G by Intravenous Bolus in AIDS and AIDS-Related Complex. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 10, 150-156.	0.3	6
592	Isolation of Herpes Simplex Virus From the Genital Tract During Symptomatic Recurrence on the Buttocks. <i>Obstetrics and Gynecology</i> , 2006, 108, 947-952.	2.4	6
593	The Acceptance of HSV-Testing Partners of HSV-2 Seronegative Pregnant Women. <i>Sexually Transmitted Diseases</i> , 2009, 36, 211-215.	1.7	6
594	Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids. <i>Journal of Clinical Virology</i> , 2011, 50, 4-7.	3.1	6

#	ARTICLE	IF	CITATIONS
595	Clinical and Virologic Response to Episodic Acyclovir for Genital Ulcers Among HIV-1 Seronegative, Herpes Simplex Virus Type 2 Seropositive African Women: A Randomized, Placebo-Controlled Trial. <i>Sexually Transmitted Diseases</i> , 2012, 39, 21-24.	1.7	6
596	The path to find an HIV vaccine. <i>Journal of the International AIDS Society</i> , 2021, 24, e25749.	3.0	6
597	Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	3.3	6
598	Chlamydia pneumoniae respiratory infection after allogeneic stem cell transplantation. <i>Transplantation</i> , 2002, 73, 1002-1005.	1.0	6
599	Inadequacy of Plasma Acyclovir Levels at Delivery in Patients With Genital Herpes Receiving Oral Acyclovir Suppressive Therapy in Late Pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2009, 31, 1137-1143.	0.7	5
600	Xenotropic murine leukemia virus-related virus in monozygotic twins discordant for chronic fatigue syndrome. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 66-71.	1.8	5
601	The aspirational necessity of HIV prevention. <i>Journal of the International AIDS Society</i> , 2019, 22, e25289.	3.0	5
602	Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 998-1009.	1.1	5
603	Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 304-319.	4.1	5
604	The Natural History of Genital Herpes Simplex Virus. , 1985, , 1-35.		5
605	Herpes Simplex Virus. , 2010, , 1943-1962.		5
606	Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. <i>Blood</i> , 2000, 96, 2055-2061.	1.4	5
607	Innovative vaccine approaches—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1511, 59-86.	3.8	5
608	HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens. <i>Frontiers in Immunology</i> , 2022, 13, 867962.	4.8	5
609	Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 405-413.	2.1	5
610	Cesarean delivery in women with genital herpes in Washington state, 1989-1991. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 1997, 5, 29-35.	1.5	4
611	Letter to the editor: human herpesvirus 6 serologic responses. <i>Journal of Clinical Virology</i> , 2001, 21, 103-104.	3.1	4
612	A siege of hepatitis: Fighting a defiant virus. <i>Nature Medicine</i> , 2011, 17, 253-254.	30.7	4

#	ARTICLE	IF	CITATIONS
613	Viral Kinetic Correlates of Cytomegalovirus Disease and Death after Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S20.	2.0	4
614	Fatal Human Metapneumovirus Infection in Stem Cell Transplant Recipients.. <i>Blood</i> , 2004, 104, 189-189.	1.4	4
615	HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV-1 replication and cell death. <i>Journal of Clinical Investigation</i> , 2008, 118, 1974-1974.	8.2	4
616	Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, , ,	1.5	4
617	Accelerating clinical trial development in vaccinology: COVID-19 and beyond. <i>Current Opinion in Immunology</i> , 2022, 76, 102206.	5.5	4
618	Cervical Antibodies to Herpes Simplex Virus Proteins in Pregnancy and Puerperium: A Pilot Study. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 1996, 4, 7-15.	1.5	3
619	Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert. <i>Vaccine</i> , 2006, 24, 532-539.	3.8	3
620	The Effect of Imatinib on Cytomegalovirus Reactivation in Hematopoietic Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2009, 49, e120-e123.	5.8	3
621	CDC Recommendations for Opt-Out HIV Testing. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 274.	7.4	3
622	Clinician and Patient Recognition of Anogenital Herpes Disease in HIV Positive Men Who Have Sex With Men. <i>Sexually Transmitted Diseases</i> , 2011, 38, 833-836.	1.7	3
623	Reevaluating HIV Vaccine Clinical Trials Policy for Infants. <i>Journal of Infectious Diseases</i> , 2015, 211, 501-503.	4.0	3
624	In Situ Staining and Laser Capture Microdissection of Lymph Node Residing SIV Gag-Specific CD8+ T cells—A Tool to Interrogate a Functional Immune Response Ex Vivo. <i>PLoS ONE</i> , 2016, 11, e0149907.	2.5	3
625	Random-Reaction-Seed Method for Automated Identification of Neurite Elongation and Branching. <i>Scientific Reports</i> , 2019, 9, 2908.	3.3	3
626	Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. <i>Vaccine</i> , 2020, 38, 5814-5821.	3.8	3
627	Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 434-439.	2.1	3
628	Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial. <i>JAMA Network Open</i> , 2022, 5, e2215984.	5.9	3
629	Cell-mediated immunity in human herpesvirus infection: Analysis by monoclonal antibodies. <i>Clinical Immunology and Immunopathology</i> , 1985, 37, 83-92.	2.0	2
630	Detection of Hepatitis C Virus RNA in Normal Cervical Smears. <i>Clinical Infectious Diseases</i> , 2003, 37, 314-314.	5.8	2

#	ARTICLE	IF	CITATIONS
631	One shot forward for HIV prevention. <i>Nature Medicine</i> , 2014, 20, 241-242.	30.7	2
632	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. <i>Vaccine</i> , 2015, 33, 749-752.	3.8	2
633	The association of β 7 expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies. <i>EBioMedicine</i> , 2020, 62, 103102.	6.1	2
634	Behind the Scenes Heroes: The COVID-19 Vaccine Data and Safety Monitoring Board. <i>Journal of Infectious Diseases</i> , 2021, 224, 1993-1994.	4.0	2
635	Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , 1999, 94, 4029-4035.	1.4	2
636	Correction: Effects of Acyclovir and Meperidine. <i>Annals of Internal Medicine</i> , 1986, 104, 449.	3.9	2
637	Special Issues in Clinical Trials of New Anti-Infective Drugs for the Treatment of Sexually Transmitted Diseases. <i>Clinical Infectious Diseases</i> , 1992, 15, S96-S98.	5.8	1
638	Commentary: Lack of detection of HSV DNA in PBMCs and lymph nodes of HIV-infected persons. <i>Journal of Medical Virology</i> , 1996, 48, 47-47.	5.0	1
639	Reply. <i>Journal of Infectious Diseases</i> , 1999, 180, 572-574.	4.0	1
640	Genital Herpes Complicating Pregnancy. <i>Obstetrics and Gynecology</i> , 2006, 107, 426.	2.4	1
641	Varicella Zoster Virus CNS Disease in Hematopoietic Cell Transplantation: A Single Center Experience. <i>International Journal of Infectious Diseases</i> , 2008, 12, S21.	3.3	1
642	Reply to Richie and Villasante. <i>Journal of Infectious Diseases</i> , 2013, 207, 690-692.	4.0	1
643	Outcome of Hematopoietic Cell Transplantation (HCT) in Patients with Invasive Fungal Infection before HCT Without Regression or Stabilization of Radiographic Signs. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S392.	2.0	1
644	A CAR RNA FISH assay to study functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue. <i>Scientific Reports</i> , 2021, 11, 12921.	3.3	1
645	Antiretroviral Therapy in Primary HIV. <i>Advances in Experimental Medicine and Biology</i> , 1999, 458, 223-227.	1.6	1
646	Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43. <i>Viruses</i> , 2021, 13, 2075.	3.3	1
647	The Treatment of Persons Exposed to Rabies-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1975, 234, 383.	7.4	0
648	Recent Developments in the Prevention of Rabies. <i>Southern Medical Journal</i> , 1978, 71, 11-12.	0.7	0

#	ARTICLE	IF	CITATIONS
649	Topical Idoxuridine in the Treatment of Genital Herpes-Reply. JAMA - Journal of the American Medical Association, 1983, 249, 1827.	7.4	0
650	Genital Herpes and Erythema Multiforme-Reply. JAMA - Journal of the American Medical Association, 1983, 249, 1566.	7.4	0
651	Chronic Fatigue Syndrome-Reply. JAMA - Journal of the American Medical Association, 1991, 265, 358.	7.4	0
652	Introduction. Clinical Infectious Diseases, 1993, 16, S1-S1.	5.8	0
653	Recurrence Rates of Genital Herpes. Annals of Internal Medicine, 1995, 122, 883.	3.9	0
654	Cesarean Delivery in Women With Genital Herpes in Washington State, 1989â€“1991. Infectious Diseases in Obstetrics and Gynecology, 1997, 5, 29-35.	1.5	0
655	Genital Herpes Complicating Pregnancy. Obstetrics and Gynecology, 2006, 107, 741.	2.4	0
656	HIV vaccine effectiveness and the mucosal interface. Future HIV Therapy, 2007, 1, 127-129.	0.4	0
657	Bridging the Gaps between Fundamental, Preclinical and Clinical Research: Report from a Global HIV Vaccine Enterprise Working Group. Nature Precedings, 2010, , .	0.1	0
658	Bridging the Gaps between Fundamental, Preclinical and Clinical Research: Report from a Global HIV Vaccine Enterprise Working Group. Nature Precedings, 2010, , .	0.1	0
659	Adoptive Immunotherapy of Human Diseases with Antigen-Specific T-Cell Clones. , 2000, , 29-44.		0
660	A Large Cohort Analysis of CMV Viral Load and Ganciclovir-Related Neutropenia in Nonmyeloablative (NM-HCT) and Myeloablative (M-HCT) Allogeneic Hematopoietic Cell Transplant Recipients.. Blood, 2007, 110, 2975-2975.	1.4	0
661	HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. Journal of Clinical Investigation, 2010, 120, 3401-3401.	8.2	0
662	Electron Microscopic observation on the semen of HIV-positive men. Proceedings Annual Meeting Electron Microscopy Society of America, 1990, 48, 348-349.	0.0	0
663	Cervical antibodies to herpes simplex virus proteins in pregnancy and puerperium: A pilot study. Infectious Diseases in Obstetrics and Gynecology, 1996, 4, 7-15.	1.5	0
664	Characteristics of Primary HIV Infection. Annals of Internal Medicine, 1999, 130, 80.	3.9	0
665	Title is missing!. , 2020, 16, e1007626.		0
666	Title is missing!. , 2020, 16, e1007626.		0

#	ARTICLE	IF	CITATIONS
667	Title is missing!. , 2020, 16, e1007626.		0
668	Title is missing!. , 2020, 16, e1007626.		0